This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Real validated CCR7 Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-CCR7 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
| Expected band | ~42.9 kDa | |
| Gel | 12–15% (standard starting point) | |
| Positive control | Colon (IHC candidate; verify WB) +4 more | |
| Negative control | Adipose tissue (IHC candidate; verify WB) |
| PTM | Glycosylated + Cleaved | |
| Caveat | Glycosylation-state controls | |
| Gene-set association | MSigDB Hallmark membership | |
| Isoform | 1 isoform(s) |
The A00390 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | human spleen tissue lysate (catalog A00390) |
| Gel % | 12–15% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Standard semi-dry transfer; verify efficiency (standard starting point) |
| Membrane | 0.45 µm PVDF (standard starting point) |
| Blocking | 5% milk or 5% BSA in TBST (standard starting point) |
| Primary antibody | A00390 · 1 μg/ml (catalog A00390) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | Species-matched HRP conjugate at validated dilution (standard starting point) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
CCR7 has a predicted precursor mass of 42.9 kDa; signal peptide cleavage and Asn36 glycosylation may affect migration, but no empirical band size is supplied.
| Band near 42.9 kDa | Consistent with the predicted CCR7 precursor mass; identity needs confirmation. |
| Band below 42.9 kDa | Could reflect removal of the 1–24 signal peptide; mature migration is not established. |
| Band above 42.9 kDa | Could reflect N-linked glycosylation at Asn36; the size effect is not established. |
| Faint or absent band in lysate | Membrane-localized CCR7 may be poorly recovered during extraction. |
| Predicted precursor mass | Provides a 42.9 kDa reference, not a measured band position. |
| N-linked glycosylation at Asn36 | May increase apparent size if occupied; no shift is quantified. |
| Signal peptide at residues 1–24 | Its cleavage would make the mature chain smaller than the precursor. |
| Mature chain after signal peptide cleavage | Its apparent size is not supplied and cannot be calculated from the feature alone. |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | Membrane-localized CCR7 may be poorly extracted. | Check membrane protein recovery and use a positive lysate control. |
| Band higher than expected | N-linked glycosylation at Asn36 is possible, but its effect is unproven. | Compare treated and untreated samples and confirm band identity. |
| Band lower than expected | Signal peptide cleavage could reduce size. | Check antibody epitope coverage and confirm identity with a second antibody. |
| Multiple bands | Precursor processing or Asn36 glycosylation could contribute; distinct bands are not established. | Compare glycosidase-treated samples and validate bands with a second antibody. |
| Weak or no signal | Recovery or detection of this membrane receptor may be limited. | Check extraction, loading, transfer and a positive control. |
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Colon | endothelial cells | High | Protein (IHC) | HPA → |
| Lung | alveolar cells | High | Protein (IHC) | HPA → |
| Lymph node | non-germinal center cells | High | Protein (IHC) | HPA → |
| Rectum | peripheral nerve/ganglion | High | Protein (IHC) | HPA → |
| Skin | cells in corneal layer | High | Protein (IHC) | HPA → |
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | glandular cells | Not detected | Protein (IHC) | HPA → |
| Appendix | endocrine cells | Not detected | Protein (IHC) | HPA → |
| Breast | adipocytes | Not detected | Protein (IHC) | HPA → |
| Bronchus | respiratory epithelial cells | Not detected | Protein (IHC) | HPA → |
Deeper troubleshooting and optimisation questions for CCR7, answered from its protein features.
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Two the supplier anti-CCR7 antibodies have WB images: A00390 in human spleen lysate and M00390 in human cell, rat tissue and cell, and mouse tissue lysates. These images document the stated samples and conditions, not universal validation across each species.
Which to pick: For human spleen lysate, consider A00390 (tested at 1 μg/ml). For human MCF-7 or K562 cells, rat samples, or mouse spleen or lung, M00390 has matching WB examples (tested at 1:500).